Data Privacy Statement / Imprint
This document contains the relevant provisions which are to be made part of the Twitter Channel as ‘Data Privacy Statement’ and ‘Imprint’.
Legal Notices are sub-categorized as follows:
Data Privacy Statement
This Twitter social media channel (hereinafter the “Social Media Channel“) from Corporate Communications is provided by Bayer AG (hereinafter “us” or “we”). For further information regarding the provider of the Social Media Channel, please refer to our imprint.
A. Handling of personal data
In the following we wish to provide you with information on how we handle your personal data when you use our Social Media Channel. Unless otherwise indicated in the following chapters, the legal basis for the handling of your personal data results from the fact that such handling is required to make available the functionalities of the Social Media Channel requested by you (Art. 6(1)(b) General Data Protection Regulation).
I. Using our Social Media Channel
1. Using comment-, message- or chat-functions
You can contact us directly via the comment-, message- or chat-functions available on our Social Media Channel. The information provided by you in this context will exclusively be processed for purposes of responding to you, unless other purposes are indicated in this Privacy Statement.
2. Information on side effects and quality complaints
This Social Media Channel is not intended or designed for communications regarding undesired side effects, lack of therapeutic effect, medication errors, grey market products/counterfeit medicine, incorrect or off-label use, quality complaints and/or other issues regarding the safeness or quality of Bayer products. If you wish to report side effects or make a quality complaint, please contact your health care professional (e.g. physician or your pharmacist), your local health authority, or use our website for the report of undesirable side effects.
If you nevertheless report to us undesirable side effects or other issues regarding the safeness or quality of Bayer products, we will be legally bound to deal with your communication and may have to may contact you for clarification purposes. Subsequently, we have to notify the competent health authorities of the issues reported by you. In this context, your information may be forwarded in pseudonymised form, i.e. no information by which you may be directly identified will be passed on. We may also have to forward these pseudonymised notifications to our group companies and cooperation partners, to the extent these are likewise obliged to notify their respectively competent health authorities.
3. Using a like-button function
Anyone who clicks the "Like" button sends information to the platform provider, who again provides us with information about the average age structure, place of residence, gender, language and activity of all users who used a “Like” button function with regard to our Social Media Channel. In addition we receive the self-selected user name when clicking a “Like” button. For more details on the data the platform provider collects in this regard, please consult the below (D) referenced privacy statement of the platform provider.
II. Social Media Management Tool
We use a social media management tool to administrate our account and manage the content we share on our Social Media Channel as well as our visitors’ engagement with us (Art. 6(1)(f) General Data Protection Regulation). For this purpose, any of your engagements with our Social Media Channel (e.g. comments, likes, posts, messages) will be transferred and stored in our social media management tool.
The social media management tool allows us to analyse the overall engagement of our visitors with our Social Media Channel to e.g.
- determine most active visitors;
- determine sentiment via automated and manual scoring;
- identify and profile brand advocates and key influencers;
- filter messages to identify and delete spam
- analyse our stakeholders into segments.
We keep a record of your engagement with us for as long as you keep regularly engaging with us. We delete your record of engagement if you have not engaged with us for more than 2 years.
III. Social Media Listening
We conduct so called social media listening. Social media listening is the process of identifying and assessing what is being said about a company, individual, product or brand on social media channels. We use social media listening services exclusively on publicly accessible content to
- perform keyword searches across social media channels;
- view the volume of conversation whenever users interact with our brand;
- view visual analytic displays of conversation trends over a specified time range;
- search, filter and analyse conversation streams and
- monitor publicly available opinions, statements or other interactions on social media channels from certain individuals or entities that are important for us and our business (so called thought leaders).
We use the insights we receive from social media listening to
- better understand sentiment, intent, mood and market trends as well as to better understand our customers’ or other stakeholders’ needs and thereby improve our services and products and
- identify side effects, lack of therapeutic effect, medication errors, grey market products/counterfeit medicine, incorrect or off-label use, quality complaints and/or other issues regarding the safety or quality of our products
We perform social media listening on the legal basis of the statutory permission which allows a processing that is necessary for pursuing a legitimate interest, namely the above described purposes on what we use the insights of social media listening for (Art. 6(1)(f) General Data Protection Regulation).
IV. Transfer of data for commissioned processing
For the administration of our Social Media Channel we will use specialised service contractors, who will have access to the personal data of all users contacting us via such Social Media Channel. Such service contractors are carefully selected and regularly monitored by us. Based on respective data processor agreements, they will only process personal data upon our instruction and strictly in accordance with our directives.
V. Processing of data outside the EU / the EEA
Your data will in part also be processed in countries outside the European Union (“EU”) or the European Economic Area (“EEA”), which generally have a lower data protection level than European countries. In such cases, we will ensure that a sufficient level of protection is provided for your data, e.g. by concluding specific agreements with our contractual partners (copy available on request), or we will ask for your explicit consent to such processing.
B. Information regarding your rights
The following rights are in general available to you according to applicable data privacy laws:
- Right of information about your personal data stored by us;
- Right to request the correction, deletion or restricted processing of your personal data;
- Right to object to a processing for reasons of our own legitimate interest, public interest, or profiling, unless we are able to proof that compelling, warranted reasons superseding your interests, rights and freedom exist, or that such processing is done for purposes of the assertion, exercise or defense of legal claims;
- Right to data portability;
- Right to file a complaint with a data protection authority;
- You may at any time with future effect revoke your consent to the collection, processing and use of your personal data. For further information please refer to the chapters above describing the processing of data based on your consent.
If you wish to exercise your rights, please address your request to the contact indicated below. (-> C.).
C. Contact
For any questions you may have with respect to data protection, please send us a private message via the message function on our Social Media Channel or contact our company data protection officer at the following address:
Group Data Protection Officer
Bayer AG
51368 Leverkusen
D. Processing of personal data by the platform provider
Please note that the platform provider of this Social Media Channel will also process your personal data when you visit our Social Media Channel. For further information, please consult the privacy statement of the platform provider of this Social Media Channel.
E. Amendment of this Privacy Statement
We may update our Privacy Statement from time to time. Updates of our Privacy Statement will be published on our Social Media Channel. Any amendments become effective upon publication on our Social Media Channel. We therefore recommend that you regularly visit the Social Media Channel to keep yourself informed on possible updates.
Imprint
Published by:
Bayer AG, Leverkusen, Germany
represented by the Management Board:
Werner Baumann, Chairman
Liam Condon, Sarena Lin, Wolfgang Nickl, Stefan Oelrich, Heiko Schipper
Kaiser-Wilhelm-Allee 1
51373 Leverkusen, Germany
Tel.: +49 (0)214 30-1
E-Mail: Inquiries can be sent to info@bayer.com or using our contact form.
Entry in the Commercial Register of the Cologne District Court
(Amtsgericht): HRB 48248
Turnover tax ID no.: DE 123659859
Edited by:
Bayer AG
Communications
> General requests
Postal address
Bayer AG
Building W 11
51368 Leverkusen, Germany
© Copyright Bayer AG, Leverkusen, Germany
Therapeutic Area | Phase | Program | Indication | NME / LCM | |
---|---|---|---|---|---|
Oncology | III | Darolutamide (AR Inhibitor) | Prostate Cancer (mHSPC) | LCM | |
Indication: Prostate Cancer (mHSPC) Type: LCM Mode-of-Action: AR Inhibitor - Type: - Partner: - |
|||||
Oncology | III | Copanlisib (PI3K Inhibitor) | Non-Hodgkin Lymphoma | LCM | |
Indication: Non-Hodgkin Lymphoma Type: LCM Mode-of-Action: Copanlisib (PI3K Inhibitor) - Type: - Partner: - |
|||||
Oncology | III | Darolutamide (AR Inhibitor) | Adjuvant Prostate Cancer | LCM | |
Indication: Adjuvant Prostate Cancer Type: LCM Mode-of-Action: Darolutamide (AR Inhibitor) - Type: - Partner: - |
|||||
Oncology | III | Regorafenib (multi-Kinase Inhibitor) | Glioblastoma | LCM | |
Indication: Glioblastoma Type: LCM Mode-of-Action: Regorafenib (multi-Kinase Inhibitor) - Type: - Partner: - |
|||||
Cardiovascular Diseases | III | Finerenone (MR Antagonist) | Heart Failure (HFmr/pEF) | LCM | |
Indication: Heart Failure (HFmr/pEF) Type: LCM Mode-of-Action: Finerenone (MR Antagonist) - Type: - Partner: - |
|||||
Cardiovascular Diseases | III | Vericiguat (sGC Stimulator) | Heart Failure (HFrEF) | LCM | |
Indication: Heart Failure (HFrEF) Type: LCM Mode-of-Action: Vericiguat (sGC Stimulator) - Type: - Partner: - |
|||||
Cardiovascular Diseases | III | Finerenone (MR Antagonist) | Non-diabetic CKD | LCM | |
Indication: Non-diabetic CKD Type: LCM Mode-of-Action: Finerenone (MR Antagonist) - Type: - Partner: - |
|||||
Women's Health | III | Elinzanetant (Neurokinin-1,3 Rec Antag.) | Vasomotor Symptoms | NME | |
Indication: Vasomotor Symptoms Type: NME Mode-of-Action: Elinzanetant (Neurokinin-1,3 Rec Antag.) - Type: - Partner: - |
|||||
Others | III | Aflibercept High Dose | Diabetic Macular Edema (DME) | LCM | |
Indication: Diabetic Macular Edema (DME) Type: LCM Mode-of-Action: Aflibercept High Dose - Type: - Partner: - |
|||||
Others | III | Aflibercept High Dose | Neovasc. Age-rel. Macular Degen. (nAMD) | LCM | |
Indication: Neovasc. Age-rel. Macular Degen. (nAMD) Type: LCM Mode-of-Action: Aflibercept High Dose - Type: - Partner: - |
|||||
Oncology | II | Regorafenib (combi Nivolumab) | Solid tumors (recurrent or metastatic) | LCM | |
Indication: Solid tumors (recurrent or metastatic) Type: LCM Mode-of-Action: Regorafenib (combi Nivolumab) - Type: - Partner: - |
|||||
Oncology | II | Regorafenib (combi Pembrolizumab) | Hepatocellular Carcinoma (HCC) | LCM | |
Indication: Hepatocellular Carcinoma (HCC) Type: LCM Mode-of-Action: Regorafenib (combi Pembrolizumab) - Type: - Partner: - |
|||||
Cardiovascular Diseases | II | Asundexian (FXIa Inhibitor) | 2⁰ Stroke Prevention | NME | |
Indication: 2⁰ Stroke Prevention Type: NME Mode-of-Action: Asundexian (FXIa Inhibitor) - |
|||||
Cardiovascular Diseases | II | Fesomersen (FXI-LICA) | Thrombosis Prevention in ESRD | NME | |
Indication: Thrombosis Prevention in ESRD Type: NME Mode-of-Action: Fesomersen (FXI-LICA) - |
|||||
Cardiovascular Diseases | II | Runcaciguat (sGC Activator) | Chronic Kidney Disease (CKD) | NME | |
Indication: Chronic Kidney Disease (CKD) Type: NME Mode-of-Action: Runcaciguat (sGC Activator) - Type: - Partner: - |
|||||
Cardiovascular Diseases | II | Asundexian (FXIa Inhibitor) | Stroke Prevention in Atrial Fibrillation | NME | |
Indication: Stroke Prevention in Atrial Fibrillation Type: NME Mode-of-Action: Asundexian (FXIa Inhibitor) - |
|||||
Cardiovascular Diseases | II | Asundexian (FXIa Inhibitor) | Major Adverse Cardiac Events Prevention | NME | |
Indication: Major Adverse Cardiac Events Prevention Type: NME Mode-of-Action: Asundexian (FXIa Inhibitor) - |
|||||
Cardiovascular Diseases | II | Osocimab (anti-FXIa Antibody) | Thrombosis Prevention in ESRD | NME | |
Indication: Thrombosis Prevention in ESRD Type: NME Mode-of-Action: Osocimab (anti-FXIa Antibody) - |
|||||
Others | II | Runcaciguat (sGC Activator) | Non-prolif. Diabetic Retinopathy (NPDR) | NME | |
Indication: Non-prolif. Diabetic Retinopathy (NPDR) Type: NME Mode-of-Action: Runcaciguat (sGC Activator) - Type: - Partner: - |
|||||
Others | II | BDKRB1 Receptor Antagonist | Neuropathic Pain | NME | |
Indication: Neuropathic Pain Type: NME Mode-of-Action: BDKRB1 Receptor Antagonist - Type: - Partner: - |
|||||
Others | II | Adrenomedullin Pegol (PEG-ADM) | Acute Resp. Distress Syn. (ARDS) | NME | |
Indication: Acute Resp. Distress Syn. (ARDS) Type: NME Mode-of-Action: Adrenomedullin Pegol (PEG-ADM) - Type: - Partner: - |
|||||
Others | II | High Relaxivity Contrast Agent (HRCA) | Magnetic Resonance Imaging | NME | |
Indication: Magnetic Resonance Imaging Type: NME Mode-of-Action: High Relaxivity Contrast Agent (HRCA) - Type: - Partner: - |
|||||
Oncology | I | Elimusertib (ATR Inhibitor) | Cancer | NME | |
Indication: Cancer Type: NME Mode-of-Action: Elimusertib (ATR Inhibitor) - Type: - Partner: - |
|||||
Oncology | I | mEGFR Inhibitor | Cancer | NME | |
Indication: Cancer Type: NME Mode-of-Action: mEGFR Inhibitor - Type: - Partner: - |
|||||
Oncology | I | Bapotulimab (ILDR2 fb Antibody) | Cancer | NME | |
Indication: Cancer Type: NME Mode-of-Action: Bapotulimab (ILDR2 fb Antibody) - Type: - Partner: - |
|||||
Oncology | I | SLFN12 Complex-Inducer | Cancer | NME | |
Indication: Cancer Type: NME Mode-of-Action: SLFN12 Complex-Inducer - Type: - Partner: - |
|||||
Oncology | I | HER2-TTC (HER2-Targeted Thorium Conjugate) | Cancer | NME | |
Indication: Cancer Type: NME Mode-of-Action: HER2-TTC (HER2-Targeted Thorium Conjugate) - |
|||||
Oncology | I | AhR Inhibitor | Cancer | NME | |
Cardiovascular Diseases | I | sGC Activator 4 | Cardiovascular Diseases | NME | |
Indication: Cardiovascular Diseases Type: NME Mode-of-Action: sGC Activator 4 - Type: - Partner: - |
|||||
Cardiovascular Diseases | I | Congestive Heart Failure Gene Therapy | Congestive Heart Failure | NME | |
Indication: Congestive Heart Failure Type: NME Mode-of-Action: Congestive Heart Failure Gene Therapy - Type: - Partner: - |
|||||
Women's Health | I | P2X4 Antagonist | Endometriosis | NME | |
Indication: Endometriosis Type: NME Mode-of-Action: P2X4 Antagonist - Type: - Partner: - |
|||||
Women's Health | I | BDKRB1 Receptor Antagonist | Endometriosis | NME | |
Indication: Endometriosis Type: NME Mode-of-Action: BDKRB1 Receptor Antagonist - Type: - Partner: - |
|||||
Others | I | Peboctocogene Camaparvovec (FVIII Gene Therapy) | Hemophilia A | NME | |
Indication: Hemophilia A Type: NME Mode-of-Action: Peboctocogene Camaparvovec (FVIII Gene Therapy) - |
|||||
Others | I | Parkinson‘s Disease Gene Therapy | Parkinson's Disease | NME | |
Indication: Parkinson's Disease Type: NME Mode-of-Action: Parkinson‘s Disease Gene Therapy - Type: - Partner: - |
|||||
Others | I | sGC Activator 3 | - | NME | |
Indication: - Type: NME Mode-of-Action: sGC Activator 3 - Type: - Partner: - |
|||||
Others | I | ADRA2C Antagonist | - | NME | |
Indication: - Type: NME Mode-of-Action: ADRA2C Antagonist - Type: - Partner: - |
|||||
Others | I | Pompe Disease Gene Therapy | Pompe Disease | NME | |
Indication: Pompe Disease Type: NME Mode-of-Action: Pompe Disease Gene Therapy - Type: - Partner: - |
|||||
Others | I | Parkinson’s Disease Cell Therapy | Parkinson's Disease | NME | |
Indication: Parkinson's Disease Type: NME Mode-of-Action: Parkinson’s Disease Cell Therapy - Type: - Partner: - |
|||||
Others | I | Zabedosertib (IRAK4 Inhibitor) | - | NME | |
Indication: - Type: NME Mode-of-Action: Zabedosertib (IRAK4 Inhibitor) - Type: - Partner: - |